(Q79330551)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14644920%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

title

Development of fluoroquinolones as first-line drugs for tuberculosis--at long last! (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14644920%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

Richard J O'Brien

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14644920%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

publication date

1 December 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14644920%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Respiratory and Critical Care Medicine

21 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14644920%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

168

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14644920%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14644920%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

1266-1268

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14644920%20AND%20SRC:MED&resulttype=core&format=json

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2309011

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2309011

Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2309011

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2309011

In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2309011

Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2309011

Application of fluoroquinolone pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2309011

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2309011

Tuberculosis. Scientific blueprint for tuberculosis drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2309011

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2309011

Studies of the early bactericidal activity of new drugs for tuberculosis: a help or a hindrance to antituberculosis drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2309011

21 January 2018

Identifiers

DOI

10.1164/RCCM.2309011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14644920%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference